Physician ATU · Brand tracker · Launch tracker

    HCP ATU study — pharmaceutical brand tracking and launch tracking

    Last updated 6 September 2026 · Laura McConaughey

    An HCP ATU (awareness, trial, usage) study is a quantitative physician tracker that measures how healthcare professionals recognise, try, and prescribe a brand over time. BioNixus fields HCP ATU, physician ATU, pharmaceutical brand tracking, and launch tracking as one primary programme — not a syndicated dashboard bolt-on. A proposal is ready within 48 hours of a brief.

    Request an HCP ATU proposal

    Primary research, market access & HEOR. Proposals within 48 hours.

    HCP ATU study — pharmaceutical brand tracking and launch tracking

    An HCP ATU (awareness, trial, usage) study is a quantitative physician tracker that measures how healthcare professionals recognise, try, and prescribe a brand over time. BioNixus fields HCP ATU, physician ATU, pharmaceutical brand tracking, and launch tracking as one primary programme — not a syndicated dashboard bolt-on. A proposal is ready within 48 hours of a brief.

    • When syndicated is enoughKeep IQVIA when you need national prescription volume, share of market, or a real-world evidence feed. Those products report what was dispensed. They do not explain why a specialist has not trialled your brand, or whether the message landed.
    • When to brief BioNixusBrief an HCP ATU when you are launching, defending share, or the affiliate cannot see trial and usage among named specialties in a named country. That is the study type a Head of Insights puts on the RFP.
    • Coverage48 countries. Local field teams. Account-level and SKU-level cuts. 48 hours from brief to proposal.

    An HCP ATU (awareness, trial, usage) study is a quantitative physician tracker that measures how healthcare professionals recognise, try, and prescribe a brand over time. BioNixus fields HCP ATU, physician ATU, pharmaceutical brand tracking, and launch tracking as one primary programme — not a syndicated dashboard bolt-on. A proposal is ready within 48 hours of a brief.

    When IQVIA is enough vs when to brief this study

    Keep the syndicated feed

    Keep IQVIA when you need national prescription volume, share of market, or a real-world evidence feed. Those products report what was dispensed. They do not explain why a specialist has not trialled your brand, or whether the message landed.

    Brief BioNixus

    Brief an HCP ATU when you are launching, defending share, or the affiliate cannot see trial and usage among named specialties in a named country. That is the study type a Head of Insights puts on the RFP.

    Read IQVIA alternative and what account-level data is. Country vendor shortlists stay on the listicles — this page owns the study type.

    Egypt, UAE, and Saudi Arabia

    HCP ATU studies in Egypt

    Physician ATU and brand tracking across Cairo, Alexandria, and Upper Egypt — Arabic-English instruments, EDA-aware design. Not a second Egypt ranking URL.

    HCP ATU studies in the UAE

    Launch tracking and physician ATU across Dubai, Abu Dhabi, and the northern emirates, designed for MOHAP, DHA, and DOH — not a Dubai convenience panel.

    HCP ATU studies in Saudi Arabia

    Brand tracking and HCP ATU in Riyadh, Jeddah, and the Eastern Province, written around SFDA and NUPCO context. Country-priced; keep IQVIA for the national audit.

    Request an HCP ATU proposal

    Primary research, market access & HEOR. Proposals within 48 hours.

    Frequently asked questions

    What is an HCP ATU study?

    HCP ATU stands for awareness, trial, and usage among healthcare professionals. It is the default quantitative brand tracker in pharma. BioNixus fields it as custom primary research — the same programme also covers physician ATU, pharmaceutical brand tracking, and launch tracking.

    Is an HCP ATU the same as an IQVIA brand audit?

    No. IQVIA audits report dispensed volume. An HCP ATU asks physicians whether they are aware of, have tried, and currently use the brand — and why. Most affiliates run both.

    Can you start tracking before launch?

    Yes. Pre-launch waves establish baseline awareness and message cut-through. Post-launch waves track trial and usage. The same instrument should run across waves so the affiliate can compare.

    How fast is a proposal?

    Within 48 hours of a brief. Typical 2026 planning bands are on the pricing page. Scope moves with specialty, sample, and number of countries.

    Related

    Healthcare market research companies

    Who to brief for primary vs syndicated work.

    Pharmaceutical market research company

    Custom primary provider vs IQVIA data platform.

    IQVIA alternative

    Keep the audit. Brief fieldwork when the cut stops at national.

    Account-level data

    Named hospital, retailer, or distributor — not a country total.

    Healthcare MR companies UAE

    Custom primary firm for Dubai and Abu Dhabi affiliates.

    Healthcare MR companies KSA

    SFDA-aware primary research vs syndicated audits.

    Market research companies Egypt

    Cairo, Alexandria, and Upper Egypt fieldwork.

    Pricing bands

    Project- and country-based 2026 ranges.

    Pharma brand tracking GCC

    Related GCC brand-tracking programmes.